1
Clinical Trials associated with PEK fusion protein vaccine(Healthbanks Biotech)Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity of a Three Dose Regimen of Escalating Doses of PEK Fusion Protein Vaccine (PEK + GPI-0100) in Patients With LSIL or HSIL
Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity of a Three Dose Regimen of Escalating Doses of PEK Fusion Protein Vaccine in Women with LSIL or HSIL.
PEK fusion protein vaccine (PEK + GPI-0100) is safe and well tolerated in patients with low-grade squamous intraepithelial lesions (LSIL) or high grade squamous intraepithelial lesions (HSIL) of the cervix and induces a measurable immune response.
100 Clinical Results associated with PEK fusion protein vaccine(Healthbanks Biotech)
100 Translational Medicine associated with PEK fusion protein vaccine(Healthbanks Biotech)
100 Patents (Medical) associated with PEK fusion protein vaccine(Healthbanks Biotech)
100 Deals associated with PEK fusion protein vaccine(Healthbanks Biotech)